Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of alverine for cirrhotic portal hypertension
ChiCTR2200063166Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of alverine in Portal Hypertension (PH) (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Hepatic venous pressure gradient (HVPG). Planned start Sep 2022; status: not yet recruiting.
02
Drugs
alverine
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on ChiCTR2200063166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063166.